Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved novel therapies such as CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and bispecific antibodies (Janssen’s Tecvayli and Talvey, and Pfizer’s Elrexfio) have expanded the number of options available. Emerging therapies—Venclexta / Venclyxto and next-generation IMiDs iberdomide and mezigdomide—will compete fiercely. Nevertheless, clinical and commercial potential remains for therapies with improved efficacy and therapies able to treat underserved patient populations, such as those with smoldering multiple myeloma.
Questions answered
- What is the size of the drug-treatable multiple myeloma population, and how do drug-treatment rates vary by geography, line of therapy, and over time?
- How will the use of Revlimid and Velcade change over the forecast period, and what impact will generic entry have on the market?
- How will physicians manage the treatment sequencing of BCMA-targeted therapies such as CAR T cells, antibody-drug conjugates, and bispecific antibodies?
- What are thought leaders’ opinions of therapies in late-stage development, such as the bispecific antibody cevostamab, the apoptosis-inducing agent Venclexta / Venclyxto, and the CELMoDs iberdomide and mezigdomide?
- What are the drivers of, and constraints on, the therapy market?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: 18 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research
Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and symptomatic status
Emerging therapies: Phase 3: 5 drugs; coverage of select Phase 1 and 2 products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Multiple Myeloma - Key Findings
- Key Updates
- October 2023
- June 2023
- May 2023
- Q1 2023
- January 2023
- Q4 2022
- November 2022
- Market Outlook
- Key findings
- Major-market share of drug classes for multiple myeloma: 2022
- Major-market share of drug classes for multiple myeloma: 2032
- Drug-treatable population share and major-market sales share in multiple myeloma: 2022
- Drug-treatable population share and major-market sales share in multiple myeloma: 2032
- Population positioning of current therapies in multiple myeloma
- Population positioning of emerging therapies in multiple myeloma
- Multiple myeloma SWOT analysis
- Market drivers and constraints
- What factors are driving the market for multiple myeloma?
- What factors are constraining the market for multiple myeloma?
- Segment-specific trends
- Smoldering multiple myeloma
- First-line transplant-eligible multiple myeloma
- Patient-share dynamics of key regimens in first-line transplant-eligible multiple myeloma in the United States: 2022-2032
- First-line transplant-ineligible multiple myeloma
- Patient-share dynamics of key regimens in first-line transplant-ineligible multiple myeloma in the United States: 2022-2032
- Relapsed / refractory multiple myeloma
- Patient-share dynamics of key regimens in second-line multiple myeloma in the United States: 2022-2032
- Patient-share dynamics of key regimens in third-line multiple myeloma in the United States: 2022-2032
- Patient-share dynamics of key regimens in fourth-line multiple myeloma in the United States: 2022-2032
- Patient-share dynamics of key regimens in fifth- to seventh-line multiple myeloma in the United States: 2022-2032
- Key findings
- Forecast
- Market forecast downloads
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Clinical manifestations of multiple myeloma
- Disease pathophysiology
- Overview
- Plasma cell and myeloma cell process
- Risk factors
- Select risk factors associated with multiple myeloma
- Staging and classification
- Classification of multiple myeloma
- Revised IMWG classification criteria of select plasma cell disorders
- Staging of multiple myeloma
- Durie-Salmon staging system for multiple myeloma
- International staging system for multiple myeloma
- Key pathways and drug targets
- Drug targets and potential therapies for multiple myeloma
- IMiD-mediated disruption of myeloma cell-microenvironment interactions
- Potentially synergistic antitumor effects of proteasome and aggresome pathways
- Biology of selective inhibitors of nuclear export (SINE)
- Biology of B-cell maturation antigen (BCMA)
- Aminopeptidases in apoptosis of myeloma cells
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed incident cases of multiple myeloma: 2022-2032
- Disease definition, methods, and sources used
- Diagnosed incident cases of multiple myeloma by symptoms: 2022-2032
- Disease definition, methods, and sources used
- Asymptomatic cases progressing to symptomatic cases of multiple myeloma: 2022-2032
- Drug-treatable cases of multiple myeloma: 2022-2032
- Multiple myeloma patient flow
- Drug-treated cases of multiple myeloma: 2022-2032
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for multiple myeloma
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for multiple myeloma
- Current treatments used for multiple myeloma
- Market events impacting the use of key current therapies in multiple myeloma
- Key results from select clinical trials investigating Darzalex / Darzalex Faspro for the treatment of multiple myeloma
- Ongoing clinical development of Darzalex / Darzalex Faspro
- Key ongoing clinical trials of Darzalex / Darzalex Faspro in the treatment of multiple myeloma
- Expert insights: Darzalex / Darzalex Faspro
- Sarclisa
- Key results from select clinical trials investigating Sarclisa for the treatment of multiple myeloma
- Ongoing clinical development of Sarclisa
- Key ongoing clinical trials of Sarclisa in the treatment of multiple myeloma
- Expert insights: Sarclisa
- Key results from select clinical trials investigating Empliciti for the treatment of multiple myeloma
- Ongoing clinical development of Empliciti
- Key ongoing clinical trials investigating Empliciti in the treatment of multiple myeloma
- Expert insights: Empliciti
- Key results from select clinical trials investigating lenalidomide for the treatment of multiple myeloma
- Ongoing clinical development of lenalidomide
- Key ongoing clinical trials of lenalidomide in the treatment of multiple myeloma
- Expert insights: lenalidomide
- Key results from select clinical trials investigating Pomalyst / Imnovid for the treatment of multiple myeloma
- Ongoing clinical development of Pomalyst / Imnovid
- Key ongoing clinical trials investigating Pomalyst / Imnovid in the treatment of multiple myeloma
- Key results from select clinical trials investigating thalomid / thalidomide / thaled for the treatment of multiple myeloma
- Key results from select clinical trials investigating bortezomib for the treatment of multiple myeloma
- Ongoing clinical development of bortezomib
- Key ongoing clinical trials investigating bortezomib in the treatment of multiple myeloma
- Key results from select clinical trials investigating Kyprolis for the treatment of multiple myeloma
- Ongoing clinical development of Kyprolis
- Key ongoing clinical trials of Kyprolis in the treatment of multiple myeloma
- Key results from select clinical trials investigating Ninlaro for the treatment of multiple myeloma
- Ongoing clinical development of Ninlaro
- Key ongoing clinical trials of Ninlaro in the treatment of multiple myeloma
- Expert insights: Ninlaro
- Key results from select clinical trials investigating Abecma for the treatment of multiple myeloma
- Ongoing clinical development of Abecma
- Key ongoing clinical trials of Abecma in the treatment of multiple myeloma
- Expert insights: Abecma
- Key results from select clinical trials investigating Carvykti for the treatment of multiple myeloma
- Analysis of the clinical development program for Carvykti
- Key ongoing clinical trials investigating Carvykti in the treatment of multiple myeloma
- Expert insights: Carvykti
- Xpovio / Nexpovio
- Key results from select clinical trials investigating Xpovio / Nexpovio for the treatment of multiple myeloma
- Ongoing clinical development of Xpovio / Nexpovio
- Expert insights: Xpovio / Nexpovio
- Key results from select clinical trials investigating Blenrep for the treatment of multiple myeloma
- Ongoing clinical development of Blenrep
- Key ongoing clinical trials of Blenrep in the treatment of multiple myeloma
- Expert insights: Blenrep
- Tecvayli
- Key results from select clinical trials investigating Tecvayli for the treatment of multiple myeloma
- Analysis of the clinical development program for Tecvayli
- Key ongoing clinical trials investigating Tecvayli in the treatment of multiple myeloma
- Expert insights: Tecvayli
- Key results from select clinical trials investigating Elrexfio for the treatment of multiple myeloma
- Analysis of the clinical development program for Elrexfio
- Key ongoing clinical trials investigating Elrexfio in the treatment of multiple myeloma
- Expert insights: Elrexfio
- Talvey
- Key results from select clinical trials investigating Talvey for the treatment of multiple myeloma
- Analysis of the clinical development program for Talvey
- Key ongoing clinical trials investigating Talvey in the treatment of multiple myeloma
- Expert insights: talquetamab
- Key results from select clinical trials investigating Pepaxto / Pepaxti for the treatment of multiple myeloma
- Key results from select clinical trials investigating Farydak for the treatment of multiple myeloma
- Ongoing clinical development of Farydak
- Medical practice
- Asymptomatic multiple myeloma
- First-line transplant-eligible multiple myeloma
- First-line transplant-ineligible multiple myeloma
- Relapsed / refractory multiple myeloma
- Patient characteristics influencing drug selection in multiple myeloma
- Treatment decision tree for multiple myeloma: United States
- Treatment decision tree for multiple myeloma: Europe
- Treatment decision tree for multiple myeloma: Japan
- Key findings
- Unmet Need Overview
- Attainment of unmet needs
- Current and future attainment of unmet needs in multiple myeloma
- Top unmet needs in multiple myeloma: current and future attainment
- Attainment of unmet needs
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for multiple myeloma
- Estimated market authorization dates of key emerging therapies for the treatment of multiple myeloma
- Key results from select clinical trials investigating cevostamab for the treatment of multiple myeloma
- Analysis of the clinical development program for cevostamab
- Key ongoing clinical trials investigating cevostamab in the treatment of multiple myeloma
- Expert insights: cevostamab
- Expectations for launch and sales opportunity of cevostamab in multiple myeloma
- Key results from select clinical trials investigating linvoseltamab for the treatment of multiple myeloma
- Analysis of the clinical development program for linvoseltamab
- Key ongoing clinical trials investigating linvoseltamab in the treatment of multiple myeloma
- Expectations for launch and sales opportunity of linvoseltamab in multiple myeloma
- Iberdomide
- Key results from select clinical trials investigating iberdomide for the treatment of multiple myeloma
- Analysis of the clinical development program for iberdomide
- Key ongoing clinical trials investigating iberdomide in the treatment of multiple myeloma
- Expert insights: iberdomide
- Expectations for launch and sales opportunity of iberdomide in multiple myeloma
- Key results from select clinical trials investigating mezigdomide for the treatment of multiple myeloma
- Analysis of the clinical development program for mezigdomide
- Key ongoing clinical trials investigating mezigdomide in the treatment of multiple myeloma
- Expectations for launch and sales opportunity of mezigdomide in multiple myeloma
- Key results from select clinical trials investigating Venclexta / Venclyxto for the treatment of multiple myeloma
- Analysis of the clinical development program for Venclexta / Venclyxto
- Key ongoing clinical trials of Venclexta / Venclyxto in the treatment of multiple myeloma
- Expert insights: Venclexta / Venclyxto
- Expectations for market authorization and sales opportunity of Venclexta / Venclyxto in multiple myeloma
- Early-phase pipeline analysis
- Select compounds in early-phase development for multiple myeloma
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in multiple myeloma: United States
- General reimbursement environment: United States
- Key market access considerations in multiple myeloma: EU5
- General reimbursement environment: EU5
- Key market access considerations in multiple myeloma: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Multiple myeloma bibliography
- Key Findings
Louis Perdios, M.Chem., M.Res., Ph.D., Manager, Healthcare Research & Data Analytics, Oncology. Dr. Perdios oversees a team of analysts who produce syndicated primary and secondary market research reports containing disease-specific insights. He has many years of experience in pharmaceutical analytics and has worked in multiple therapy areas on market forecasting, market research, branding, and life-cycle management projects. Previously, he worked at Airfinity as a lead healthcare analyst, specializing in hematological malignancies. Dr. Perdios also held senior analyst positions in oncology at GlobalData and IQVIA. He completed his Ph.D. in structural biology at Imperial College London, in collaboration with UCL and AstraZeneca, and holds an M.Res. in drug discovery and development from Imperial College London. He also holds a master’s degree in medicinal chemistry from the University of Newcastle upon Tyne.
Joan Tur, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Tur conducts market research and forecasting in a range of oncology indications. He has several years of experience as a pharmaceutical industry analyst with the Cortellis Competitive Intelligence group, serving as the team’s immuno-oncology expert. Prior to joining Clarivate, Dr. Tur was a researcher in inflammation and macrophage biology at the Barcelona Science Park. He holds a Ph.D. in biomedicine, an M.Sc. in immunology, and a B.Sc. in biology from the University of Barcelona.